India once again established its position as a reliable partner in Covid-19 assistance. It dispatched Covishield to Bahrain and Sri Lanka under the Vaccine Maitri Initiative. Sri Lanka to receive a consignment of 50,400 doses, while Bahrain to get 10,800 doses. Covishield developed by Serum Institute of India was loaded to cargo aircraft at Mumbai. The cargo aircraft left Mumbai airport as per schedule at 7:55 am for Manama. The vaccine consignment for Colombo, which delayed for 15 minutes, left at 9:00 am. Meanwhile, India has supplied vaccines to its neighbours under neighbourhood first policy. Bhutan, Maldives, Nepal, Myanmar, Sri Lanka, Afghanistan, Bangladesh received vaccines. India sees international cooperation in the area of fight against Covid-19 as its duty. New Delhi has played the role of the first responder in the region.
Credit: HT Digital Content Duration: 01:29Published
Serum Institute of India's vaccine consignment arrived at Mumbai's Chhatrapati Shivaji Maharaj International Airport on January 28. The consignment containing COVID-19 vaccine will be dispatched to Bahrain and Colombo today. India is helping other countries with the import of COVID vaccine amid the pandemic.
Congress leader Manish Tewari has lashed out at the government over the approval given to Covaxin for the first phase of trials. The Congress leader raised questions over the efficacy of the indigenously developed Covaxin, which is in the third phase of trials and has been cleared for restricted emergency use by the Drugs Controller General of India. ‘Government should act in a manner whereby there's complete confidence in people. You can't use rollout as phase 3 trial, Indians are not guinea pigs,’ Manish Tewari said. The former minister’s remarks come after government hinted that people will not be allowed to choose from the two vaccines recently approved. The first phase of coronavirus vaccination is all set to begin on 16th January, 2021. Watch the full video for all the details.
Credit: HT Digital Content Duration: 01:40Published
The Government of India announced the launch date of its mass immunisation programme against Covid-19. The vaccinations will begin on January 16, 2021. On January 3, India's drug regulator DCGI had cleared 2 vaccines - Covaxin and Covishield - for emergency use. Covaxin, made by Bharat Biotech, will be used under clinical trial conditions, as per the government. Covishield was developed by Oxford university and pharma major AstraZeneca, and is being made in India by Serum Institute of India (SII). Around 30 crore people are being targeted for vaccination in phase 1. These include healthcare staff, frontline workers like police, those aged above 50, and those aged below 50 but with co-morbidities. Watch the full video for more.
Credit: HT Digital Content Duration: 01:34Published
ICMR DG Dr. Balram Bhargava explained the DCGI nod to two Covid-19 vaccines in India. Dr. Bhargava spoke on the various studies done over Covishield and Covaxin. Covishield Oxford-AstraZeneca vaccine which is manufactured at Pune’s Serum Institute of India (SII). Covishield was the first vaccine in India to get the DCGI nod. Soon after, DCGI approved Covaxin. Watch the full video for more details.
Credit: HT Digital Content Duration: 04:32Published
Serum Institute of India (SII) CEO Adar Poonawalla on January 22 informed that there is no impact of fire on the production of 'Covishield' vaccine. "The extent of the damage is more than 1,000 crores...
Serum Institute of India (SII), CEO Adar Poonawalla received a COVISHIELD vaccine shot on January 16. COVISHIELD vaccine is manufactured by SII. India has approved 2 vaccines - Covishield and Covaxin...
Serum Institute of India (SII) on Sunday said it is ready to roll out Covishield vaccine in the country in the coming weeks after receiving approval from the... Mid-Day Also reported by •BGR India •IndiaTimes •DNA •Hindu •Indian Express